Literature DB >> 34856853

BCG vaccination strategies against tuberculosis: updates and perspectives.

Mengjin Qu1,2, Xiangmei Zhou1,2, Hao Li1,3.   

Abstract

Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB). However, BCG has variable efficacy and cannot completely prevent TB infection and transmission. Therefore, the worldwide prevalence of TB calls for urgent development of a more effective TB vaccine. In the absence of other approved vaccines, it is also necessary to improve the efficacy of BCG itself. Intravenous (IV) BCG administration and BCG revaccination strategies have recently shown promising results for clinical usage. Therefore, it is necessary for us to revisit the BCG vaccination strategies and summarize the current research updates related to BCG vaccination. This literature review provides an updated overview and perspectives of the immunization strategies against TB using BCG, which may inspire the following research on TB vaccine development.

Entities:  

Keywords:  BCG; BCG revaccination; tuberculosis; vaccine routes

Mesh:

Substances:

Year:  2021        PMID: 34856853      PMCID: PMC8903987          DOI: 10.1080/21645515.2021.2007711

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  110 in total

Review 1.  BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis--review.

Authors:  Thereza Christina Benévolo-de-Andrade; Renata Monteiro-Maia; Catherine Cosgrove; Luiz Roberto R Castello-Branco
Journal:  Mem Inst Oswaldo Cruz       Date:  2005-09-15       Impact factor: 2.743

2.  BCG vaccine elicits both T-cell mediated and humoral immune responses directed against mycobacterial lipid components.

Authors:  Yoshiyuki Watanabe; Eiji Watari; Isamu Matsunaga; Kenji Hiromatsu; Christopher C Dascher; Tetsuo Kawashima; Yoshihiko Norose; Kazuo Shimizu; Hidemi Takahashi; Ikuya Yano; Masahiko Sugita
Journal:  Vaccine       Date:  2006-05-11       Impact factor: 3.641

3.  Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.

Authors:  Mark Hatherill; Thomas J Scriba; Sara Suliman; Hennie Geldenhuys; John L Johnson; Jane E Hughes; Erica Smit; Melissa Murphy; Asma Toefy; Lesedi Lerumo; Christiaan Hopley; Bernadette Pienaar; Phalkun Chheng; Elisa Nemes; Daniel F Hoft; Willem A Hanekom; W Henry Boom
Journal:  J Immunol       Date:  2016-07-13       Impact factor: 5.422

4.  A Functional Role for Antibodies in Tuberculosis.

Authors:  Lenette L Lu; Amy W Chung; Tracy R Rosebrock; Musie Ghebremichael; Wen Han Yu; Patricia S Grace; Matthew K Schoen; Fikadu Tafesse; Constance Martin; Vivian Leung; Alison E Mahan; Magdalena Sips; Manu P Kumar; Jacquelynne Tedesco; Hannah Robinson; Elizabeth Tkachenko; Monia Draghi; Katherine J Freedberg; Hendrik Streeck; Todd J Suscovich; Douglas A Lauffenburger; Blanca I Restrepo; Cheryl Day; Sarah M Fortune; Galit Alter
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

Review 5.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

6.  Aerosol-Induced Tuberculosis in Subhuman Primates and the Course of the Disease After Intravenous BCG Vaccination.

Authors:  W R Barclay; R L Anacker; W Brehmer; W Leif; E Ribi
Journal:  Infect Immun       Date:  1970-11       Impact factor: 3.441

7.  Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants.

Authors:  A C Hesseling; M F Cotton; C Fordham von Reyn; S M Graham; R P Gie; G D Hussey
Journal:  Int J Tuberc Lung Dis       Date:  2008-12       Impact factor: 2.373

8.  Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis.

Authors:  Debapriya Bhattacharya; Ved Prakash Dwivedi; Santosh Kumar; Madhava C Reddy; Luc Van Kaer; Prashini Moodley; Gobardhan Das
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

9.  A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.

Authors:  Miguel J Rodo; Virginie Rozot; Elisa Nemes; One Dintwe; Mark Hatherill; Francesca Little; Thomas J Scriba
Journal:  PLoS Pathog       Date:  2019-03-04       Impact factor: 6.823

10.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

Authors:  Michele D Tameris; Mark Hatherill; Bernard S Landry; Thomas J Scriba; Margaret Ann Snowden; Stephen Lockhart; Jacqueline E Shea; J Bruce McClain; Gregory D Hussey; Willem A Hanekom; Hassan Mahomed; Helen McShane
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.